The aim of the trial was to compare the pharmacokinetics and mosquito-killing effect of 300 mcg/kg of IVM given on three consecutive days to 400 mcg/kg of IVM given once. The trial also evaluated how the two treatments differed from albendazole in terms of mosquito survival
Mosquitocidal effect and pharmacokinetics of different ivermectin dose regimens given to both male and female healthy participants who were willing to comply with study requirements. The study participants were residents of Ngerenya, Kilifi, Kenya
The datasets describe the process of screening the participants and randomization into the study arms for eligible individuals. Participants screened 30 days to study allocation were screened again to check on their eligibility. Participants were treated and followed up according to the group to which the participant was assigned. Participants who were dropped off from the study were registered in the withdrawal form.
The trial is registered on clinicaltrials.gov: NCT04966702
Data Access: Restricted Access to these data requires submission of a formal request for consideration by our Data Governance Committee. How to request Download and complete the data request form Email completed data request form to the Data Governance Committee at dgc@kemri-wellcome.org